UC San Diego

UC San Diego Previously Published Works

Title

Searching for Small Molecules with an Atomic Sort

Permalink

https://escholarship.org/uc/item/1q05m9m2

Journal

Angewandte Chemie, 132(3)

ISSN

0044-8249

Authors

Duggan, Brendan M Cullum, Reiko Fenical, William <u>et al.</u>

Publication Date 2020-01-13

DOI

10.1002/ange.201911862

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <u>https://creativecommons.org/licenses/by/4.0/</u>

Peer reviewed





Check for

Molecular Search Engine

Searching for Small Molecules with an Atomic Sort

Brendan M. Duggan,* Reiko Cullum, William Fenical, Luis A. Amador, Abimael D. Rodríguez, and James J. La Clair*

Abstract: The discovery of biologically active small molecules requires sifting through large amounts of data to identify unique or unusual arrangements of atoms. Here, we develop, test and evaluate an atom-based sort to identify novel features of secondary metabolites and demonstrate its use to evaluate novelty in marine microbial and sponge extracts. This study outlines an important ongoing advance towards the translation of autonomous systems to identify, and ultimately elucidate, atomic novelty within a complex mixture of small molecules.

One of the most critical aspects in the discovery of biologically active small molecules is the elucidation of small molecular motifs with unique three-dimensional displays. The combination of this process with detailed targetbased mode of action research^[1] lies at the foundation of drug lead^[2] discovery. While automation,^[3] miniaturization,^[4] digital networking^[5] and machine learning-guided high-throughput screening^[6] have produced active leads, the bulk of screening efforts still follow a central approach that begins with a molecular ensemble, either an extract containing natural products or a smart library of synthetic compounds.^[7] Although both synthetic and natural approaches appear different, they typically apply a combination of molecular, cellular, or phenotypic screens. While effective, such approaches are often cluttered by the discovery of redundant structural features and motifs. This strategy has prevailed, in part, due to our inability to search for structural novelty.

Mass spectrometry (MS) methods, and associated profiling systems, provide an excellent means to characterize molecules, but are typically limited to databased compounds

[*]	Dr. B. M. Duggan
	Skaggs School of Pharmacy and Pharmaceutical Sciences
	9500 Gilman Drive, La Jolla, CA 92093 (USA)
	E-mail: Driduggan@ucsu.edu
	Center for Marine Biotechnology and Biomedicine, Scripps Institu- tion of Oceanography, University of California, San Diego La Jolla, CA 92093-0204 (USA)
	L. A. Amador, Prof. A. D. Rodríguez Molecular Sciences Research Center, University of Puerto Rico 1390 Ponce de León Avenue, San Juan, 00926 (Puerto Rico)
	Dr. J. J. La Clair Department of Chemistry and Biochemistry, University of California, San Diego
	E-mail: jlaclair@ucsd.edu
D	Supporting information (including experimental procedures, copies of NMR spectra, lead characterization data, as well as access to raw FID data) and the ORCID identification number(s) for the author(s)

of this article can be found under https://doi.org/10.1002/anie. 201911862.

with effective molecular ionization. For the elucidation of molecular motifs NMR spectroscopy is required, typically achieved by collecting a series of 2D spectra, which a trained user interprets to unequivocally identify every atom in the sample. Recently, computational systems to evaluate NMR data have been developed.^[8] Salient examples, such as the SMART system, allow one to rapidly identify the structural family of a purified compound.^[8b] However, these tools use NMR data to evaluate molecular species. While these approaches enable rapid clustering of a new compound with structural neighbours, they are not able to identify novel material, which for natural product lead discovery requires one to return to the classical methods of compound isolation via dereplication with repeated purification and characterization steps.

One can view a mixture of compounds simply as a collection of atoms. Since NMR reports atomic data, it will provide information on all the atoms in all the compounds present in a mixture. Since the most common atoms in molecules of pharmaceutical interest are hydrogen (H) and carbon (C), a ¹H-¹³C HSQC NMR spectrum provides a near complete map of the molecular frameworks within a screening collection. While some structural features are missed, this spectrum is routinely used by experts to classify and identify compounds, and for this reason we selected the $^1\mathrm{H}\text{-}^{13}\mathrm{C}\,\mathrm{HSQC}$ experiment as the data source for developing an objective method that could be readily automated for scoring and sorting atomic novelty.

We began by constructing a ¹H-¹³C HSQC peak database, where each peak describes a hydrogen attached to a carbon atom (Figure 1c, Supporting Figure S3) and is diagnostic of the atom's immediate atomic environment (Supporting Figures S1-S4). Using publicly available data, we abstracted peaks from spectra in the Human Metabolome Database^[9] and the BioMagResBank,^[10] and constructed peak lists from a tabulation of the chemical shifts of common solvents.^[11] The public data was supplemented with spectra of standards and natural products collected in house or obtained from the literature. The total number of peaks was 10308 obtained from 1207 spectra.

We then collected a ¹H-¹³C HSQC spectrum on a 50 µg sample of a model natural product, bromophycolide $A^{[12]}$ (Figure 1a, Supporting Figure S4, Supporting Table S1). Automated digital peak picking of this spectrum produced a peak list (Figure 1b), which was compared against the database (Figure 1c) to provide a profiled spectrum (Figure 1 d, Supporting Figure S5). A distance score for each peak in the profiled spectrum (Figure 1d) was determined by calculating the Euclidean distance to the closest peak in the database (Supporting Table S1). Since the ranges of the ¹H and ¹³C dimensions of a HSQC experiment differ by a factor



Figure 1. Searching atomic novelty in bromophycolide A. Workflow: a) The process begins by collection of a ¹H-¹³C HSQC spectrum of bromophycolide A. b) Once collected, the peaks are then digitally abstracted to provide the observed peak list (a 10 kB text file). The observed peak list is then compared one peak at a time against the HSQC database (a 850 kB text file) using the Euclidian distance algorithm. c) To illustrate this graphically, we rendered the database as a HSQC spectrum. Here, each peak within the database is represented by a grey dot. d) In a graphical representation, the peaks to be profiled (blue) are then compared to the database peaks (grey). An inset shows graphically the distance calculation made between one of the peaks to be profiled (blue) and its closest database peak (grey). Other than collecting the NMR spectrum, the steps are conducted computationally with peak lists. The graphical representation in (c), (d) is provided to visualize this process. This procedure can be used to guide isolation by following the most novel peaks. e) This results in a pure compound whose HSQC data can be f) re-subjected to the atomic novelty prioritization.

of more than 10, equal weighting of the dimensions was achieved by dividing the distances in each dimension by the total range of the chemical shifts in the database for that dimension. For the database used here, the ¹H chemical shift range was 10.25 ppm and the ¹³C range 211.6 ppm. The distance score was then expressed as a percentage, which can be thought of as the fraction of the total chemical shift range. Sorting the scores identified the most unusual chemical shifts,

an indicator of a structurally unique proton and/or carbon atom.

The four peaks A1–A4 (Figure 2) with the largest distance scores are shown in Figure 2c–f. Pleasingly, these peaks corresponded to positions of structural novelty, namely the macrocyclic aryl system at C3 and C16, halogenation at C22 and a uniquely substituted macroaromatic lactone at C14.



Figure 2. An Euclidian distance algorithm for atomic novelty scoring. a) The profiled spectrum of bromophycolide A with the top peaks A1–A4. b) The structure of bromophycolide A with A1–A4 highlighted. c–f) Graphical rendering of the Euclidian distance evaluations between the bromophycolide A peak (red point) and its closest peak in the database (black points).

Similarly, testing the algorithm with strychnine (Supporting Table S2 and Figures S6,S7), brusatol (Supporting Table S3 and Figures S8,S9), and paclitaxel (Supporting Table S4 and Figures S10,S11) also identified patterns of proton and carbon atom novelty. Like algorithms used for automated MS assignment^[13] or NMR protein structure elucidation,^[14] this scoring system provides critical information with regards to structural assignment as well as identifying regions of novelty.

After testing with pure compounds, we then evaluated the approach as a method to prioritize natural product isolation. Here, the goal was to use this method to rapidly identify extracts that may have natural products with unique structural features. As illustrated in Figure 1, the peaks with the highest novelty (Figure 1 d) can be used to guide the isolation of pure materials from the extract (Figure 1 e). ¹H-¹³C HSQC data collected on the pure material (Figure 1 e) can be

reapplied to the atomic prioritization as a means of validation (Figure 1 f).

We began by exploring extracts from a marine microbial strain. We prepared EtOAc extracts from the cultivation of a marine-derived *Streptomyces* sp., strain CNB-982, and collected ¹H-¹³C HSQC data on 52 µg of crude material (Supporting Figure S12). The peaks from this spectrum were extracted digitally, and compared against the database (Figure 3b, Supporting Table S5, Supporting Figure S13). Of the 289 peaks detected, 20 had distance scores greater than or equal to 1%.



Figure 3. Exploration of the atomic novelty search on the marine microbial extract CNB-982 identifies the cyclic peptide cyclomarin A. a) Structure of cyclomarin A along with the chemical shifts of the top scoring peaks, B1-B5, from its ¹H-¹³C HSQC spectrum in CD₃OD. b) Profiled ¹H-¹³C HSQC of the CNB-982 extract. c) Profiled ¹H-¹³C HSQC of the purified cyclomarin A. d–g) Graphical rendering of the Euclidian distance evaluations between peaks B1–B5 (red points) and closest peaks in the database (black points). Supporting Figure S1 provides chemical structures of the closest database peaks to B1–B5.

We focused our attention on the top peak in the CNB-982 extract, B1 ($\delta_{\rm H} = -0.91$, $\delta_{\rm C} = 32.4$, distance = 13.74%, Figure 3, Supporting Table S5). Using peak B1 to guide selection of chromatography fractions, we isolated 1.8 mg of a pure material. The combination of the exact mass for $[M-H_2O < M + < H]^+ m/z$ 1025.6062 observed by FAB mass spectrometry along with an expanded NMR data set (Supporting Figures S16-S19 and Supporting Table S7), enabled the pure material to be identified as cyclomarin A $(C_{56}H_{80}O_{11}N_8 \text{ calcd } 1025.6057)$ (see an expanded discussion in Supporting Figure S3).^[15] By profiling the pure cyclomarin A against the database (Figure 3c, Supporting Table S6 and Supporting Figure S13) we found the top five scoring peaks (Figure 3a) were observed in the top 16 found in the crude mixture, indicating that much of the novelty came from one compound, therein validating the approach as shown in Figure 1 f.

Inspection of peaks B1-B5 (Figure 3) was not only useful to guide isolation but provided structural information. As shown in Figure 3d, we were able to determine that the top peak B1 (orange) was one of the protons at C51, which had an unusual proton chemical shift at -0.90 ppm. Peaks B2 and B3 arose from the geminal protons C53 (blue, Figure 3e) with uncharacteristic proton shifts at 2.58 and 2.71 ppm. The fourth peak (B4, red, Figure 3 f) arose from the methyl group at C54. Peak B5 (green, Figure 3g) was assigned to the alpha carbon (C26) of the leucine residue. Interestingly, all of the top four peaks arose from (2S,4R)-2-amino-5-hydroxy-4-methyl-pentanoic acid, a rare amino acid, therein confirming the method's aptness to find structural novelty. Here, we demonstrated how this tool can be used to prioritize the isolation of materials from a crude extract. In this example, the top peak, B1, provided a clear spectroscopic beacon to guide the isolation process, and comparison with the proximal peaks in the database provided preliminary structural information (Supporting Figure S8).

Next, we tested the system with extracts from a multicellular model using a marine sponge. A ${}^{1}\text{H}{}^{-13}\text{C}$ HSQC spectrum was recorded using a 32 µg sample of a CH₂Cl₂/ MeOH extract from the marine sponge *Plakortis halichondrioides* (specimen code IM06-19) (Supporting Figure S20). Digital data extraction followed by profiling against the database (Figure 4b, Supporting Figure S21) identified several peaks for prioritization (Supporting Table S9).

Selecting peak C1 as an NMR guide (Figure 4a), we isolated 1.2 mg of pure material (Figure 4c, Supporting Figures S22,S23 and Table S9) from 1.9 g of crude extract with a HRMS sodiated molecular ion with m/z 371.2193 suggesting a formula of $C_{21}H_{32}O_4$ Na. Collection and evaluation of 1D and 2D NMR data (Supporting Figures S24–S27 and Supporting Table S10) identified the material as a new compound, gracilioether L (Figure 4a, see an expanded discussion in Supporting Figure S4), a two-carbon chain elongated homologue of gracilioether B.^[16] As shown in Figure 4d–f, the top three peaks C1–C3 were observed at the C11 *trans*-olefin (C1, Figure 4d), furanyl-C4 olefin (C2, Figure 4e) and terminal carbon C18 of an ethyl group at C6 (C3, Figure 4 f). The novelty search then identified the methyl ester C21 (peak C4, Figure 4g) as the next unique chemical



Figure 4. Exploration of the atomic novelty search on the *Plakortis* halichondrioides extract (IM06-19) identifies gracilioether L. a) Structure of gracilioether L along with the top peaks C1–C4 from ¹H-¹³C HSQC spectrum in CD₃OD. b) Profiled ¹H-¹³C HSQC of the IM06-19 extract. c) Profiled ¹H-¹³C HSQC of isolated gracilioether L. d)–g) Graphical rendering of the Euclidian distance evaluations between peaks C1–C4 observed in the spectrum of purified gracilioether L (red points) and its closest peaks in the database (black points). Supporting Figure S2 provides chemical structures of closest database peaks to C1–C4. The stereochemistry at C6 and C10 was not determined.

shift. Interestingly, these atoms are at positions where modifications are commonly observed within this large family of congeners. Further inspection of the entire prioritization (Supporting Table S9) additionally supports this conclusion, suggesting that this tool may also have applications to identify novelty within families of related natural products. Like cyclomarin A, comparing peaks C1–C4 against their proximal database peaks provided a direct structural correlation and was particularly useful in validating peak assignments (Supporting Figures S2, S4).

Overall, we have demonstrated the application of this tool to autonomously evaluate atomic novelty. These studies demonstrate how one can integrate NMR profiling as a means to identify novelty within an extract and isolate unique materials from these extracts using only micrograms of material. While one often views NMR analysis as expensive and slow, the speed and material requirements, < 6 min using a 35 μ L sample, rival those conventionally used by mass spectrometry. The fact that less than 5 min is required for data collection and 1 min for data abstraction and algorithmic processing, clearly demonstrates the practical nature of the process. Here, we found that the prioritizing of peaks was dependent on the quality of the peak list. While noise peaks rarely interfered, we found that two-bond correlations, cross peaks between atoms connected by two bonds instead of one, often scored highly. To flag these peaks we identified 99.99 % confidence limits on the database peaks. Peaks falling outside these limits were checked for shared coordinates with two other peaks. Efforts are now underway to expand this tool to flag noise and artifacts, and exclude two-bond correlations.

Angewandte

Chemie

We foresee this tool expanding to become a multicomponent algorithm that not only incorporates Euclidian distance scoring of ¹H-¹³C HSQC spectra but also includes data obtained from such spectra as ¹H-¹H-COSY, ¹H-¹H-TOCSY, ¹H-¹H-NOESY, ¹H-¹H-ROESY, ¹H-¹³C-HMBC, ¹H-¹⁵N-HSQC and ¹H-¹⁵N-HMBC, collected in a single interleaved experiment.^[17] Direct digital extraction of chemical shifts from the raw data^[18] will push the protocol closer to native computational interrogation. This in turn will expedite the growth of the database, which we anticipate will eventually be able to assign the structural features of each carbon and proton within a given molecule. While structural assignment is a key facet of the drug discovery process, the ability to search through molecular data one atom at a time offers a new perspective that can enable this system to operate through a conventional online portal, one that ideally will be united with biosynthetic genome mining tools^[19] such as antiSMASH,^[20] as well as proteomic^[21] and transcriptomic^[22] data. Ultimately, it will be interesting to understand the correlation between structural novelty and its role in inducing novel biological activity, perhaps done best one atom at a time.

Acknowledgements

This program was supported in part by funding from NIH Grant 1SC1GM086271-01A1 awarded to A.D.R., the Xenobe Research Institute to J.J.L. and NIH grant CA044848 to W.F.

Conflict of interest

The authors declare no conflict of interest.

Keywords: algorithms \cdot drug discovery \cdot molecular search engine \cdot natural products \cdot NMR spectroscopy

How to cite: Angew. Chem. Int. Ed. 2020, 59, 1144–1148 Angew. Chem. 2020, 132, 1160–1164

[1] a) S. T. Cardona, C. Selin, A. S. Gislason, *Crit. Rev. Microbiol.* **2015**, 41, 465–472; b) J. J. La Clair, *Nat. Prod. Rep.* **2010**, 27, 969–995.



- [2] J. Eder, R. Sedrani, C. Wiesmann, *Nat. Rev. Drug Discovery* 2014, 13, 577–587.
- [3] D. E. Leahy, V. Sykora, Drug Discovery Today Technol. 2013, 10, e437-e441.
- [4] P. Neuži, S. Giselbrecht, K. Länge, T. J. Huang, A. Manz, Nat. Rev. Drug Discovery 2012, 11, 620–632.
- [5] R. A. Quinn, L. F. Nothias, O. Vining, M. Meehan, E. Esquenazi, P. C. Dorrestein, *Trends Pharmacol. Sci.* 2017, 38, 143–154.
- [6] C. Scheeder, F. Heigwer, M. Boutros, Curr. Opin. Syst. Biol. 2018, 10, 43-52.
- [7] K. L. Spear, S. P. Brown, Drug Discovery Today Technol. 2017, 23, 61–66.
- [8] a) W. H. Gerwick, J. Nat. Prod. 2017, 80, 2583-2588; b) C. Zhang, Y. Idelbayev, N. Roberts, Y. Tao, Y. Nannapaneni, B. M. Duggan, J. Min, E. C. Lin, E. C. Gerwick, G. W. Cottrell, W. H. Gerwick, Sci. Rep. 2017, 7, 14243; c) F. Olivon, P. M. Allard, A. Koval, D. Righi, G. Genta-Jouve, J. Neyts, C. Apel, C. Pannecouque, L. F. Nothias, X. Cachet, L. Marcourt, F. Roussi, V. L. Katanaev, D. Touboul, J. L. Wolfender, M. Litaudon, ACS Chem. Biol. 2017, 12, 2644-2651.
- [9] D. S. Wishart, Y. D. D. Feunang, A. Marcu, A. C. C. Guo, K. Liang, R. Vázquez-Fresno, T. Sajed, D. Johnson, C. Li, N. Karu, Z. Sayeeda, E. Lo, N. Assempour, M. Berjanskii, S. Singhal, D. Arndt, Y. Liang, H. Badran, J. Grant, A. Serra-Cayuela, Y. Liu, R. Mandal, V. Neveu, A. Pon, C. Knox, M. Wilson, C. Manach, A. Scalbert, *Nucleic Acids Res.* **2018**, *46*, D1.
- [10] E. L. Ulrich, H. Akutsu, J. F. Doreleijers, Y. Harano, Y. E. Ioannidis, J. Lin, M. Livny, S. Mading, D. Maziuk, Z. Miller, E. Nakatani, C. F. Schulte, D. E. Tolmie, R. K. Wenger, H. Yao, J. L. Markley, *Nucleic Acids Res.* 2008, *36*, D402–D408.
- [11] H. E. E. Gottlieb, V. Kotlyar, A. J. Nudelman, J. Org. Chem. 1997, 62, 7512–7515.
- [12] J. Kubanek, A. C. Prusak, T. W. Snell, R. A. Giese, K. I. Hardcastle, C. R. Fairchild, W. Aalbersberg, C. Raventos-Suarez, M. E. Hay, Org. Lett. 2005, 7, 5261–5264.
- [13] a) T. R. Sandrin, P. A. Demirev, *Mass Spectrom. Rev.* 2018, *37*, 321–349; b) T. Kind, H. Tsugawa, T. Cajka, Y. Ma, Z. Lai, S. S. Mehta, G. Wohlgemuth, D. K. Barupal, M. R. Showalter, M. Arita, O. Fiehn, *Mass Spectrom. Rev.* 2018, *37*, 513–532.
- [14] a) J. M. Würz, S. Kazemi, E. Schmidt, A. Bagaria, P. Güntert, *Arch. Biochem. Biophys.* 2017, 628, 24–32; b) L. B. Andreas, T. Le Marchand, K. Jaudzems, G. Pintacuda, *J. Magn. Reson.* 2015, 253, 36–49; c) P. Güntert, *Eur. Biophys. J.* 2009, 38, 129–143; d) D. E. Zimmerman, G. T. Montelione, *Curr. Opin. Struct. Biol.* 1995, 5, 664–673.

- [15] M. K. Renner, Y.-C. Shen, X.-C. Cheng, P. R. Jensen, W. Frankmolle, C. A. Kauffman, W. Fenical, E. Lobkovsky, J. Clardy, J. Am. Chem. Soc. 1999, 121, 11273–11276.
- [16] a) M. D. Norris, M. V. Perkins, E. J. Sorensen, Org. Lett. 2015, 17, 668-671; b) C. Festa, G. Lauro, S. De Marino, M. V. D'Auria, M. Monti, C. Casapullo, A. D'Amore, B. Renga, A. Mencarelli, S. Petek, G. Bifulco, S. Fiorucci, A. Zampella, J. Med. Chem. 2012, 55, 8303-8317; c) R. Ueoka, Y. Nakao, S. Kawatsu, J. Yaegashi, Y. Matsumoto, S. Matsunaga, K. Furihata, R. W. van Soest, N. Fusetani, J. Org. Chem. 2009, 74, 4203-4207; d) F. Carmen, C. D'Amore, B. Renga, L. Gianlugi, S. De Marino, M. V. D'Auria, G. Bifulco, Mar. Drugs 2013, 11, 2314-2328.
- [17] E. Kupče, T. D. W. Claridge, Angew. Chem. Int. Ed. 2017, 56, 11779–11783; Angew. Chem. 2017, 129, 11941–11945.
- [18] a) K. Krishnamurthy, Magn. Reson. Chem. 2013, 51, 821–829;
 b) K. Krishnamurthy, A. M. Sefler, D. Russell, Magn. Reson. Chem. 2017, 55, 224–232.
- [19] a) P. N. Tran, M. R. Yen, C. Y. Chiang, H. C. Lin, P. Y. Chen, *Appl. Microbiol. Biotechnol.* 2019, 103, 3277–3287; b) L. Foulston, *Curr. Opin. Microbiol.* 2019, 51, 1–8; c) A. Alonso-Betanzos, V. Bolón-Canedo, *Adv. Exp. Med. Biol.* 2018, 1065, 607–626; d) G. Seghal Kiran, P. Ramasamy, S. Sekar, M. Ramu, S. Hassan, A. S. Ninawe, J. Selvin, *Int. J. Biol. Macromol.* 2018, 112, 1278–1288.
- [20] K. Blin, T. Wolf, M. G. Chevrette, X. Lu, C. J. Schwalen, S. A. Kautsar, H. G. Suarez Duran, E. L. C. de Los Santos, H. U. Kim, M. Nave, J. S. Dickschat, D. A. Mitchell, E. Shelest, R. Breitling, E. Takano, S. Y. Lee, T. Weber, M. H. Medema, *Nucleic Acids Res.* 2017, 45, W36–W41.
- [21] a) J. Griss, *Proteomics* 2016, 16, 729-740; b) K. G. Calderón-González, J. Hernández-Monge, M. E. Herrera-Aguirre, J. P. Luna-Arias, *Adv. Exp. Med. Biol.* 2016, 919, 281-341; c) B. Turriziani, A. von Kriegsheim, S. R. Pennington, *Adv. Exp. Med. Biol.* 2016, 919, 383-396.
- [22] a) G. C. A. Amos, T. Awakawa, R. N. Tuttle, A. C. Letzel, M. C. Kim, Y. Kudo, W. Fenical, B. S. Moore, P. R. Jensen, *Proc. Natl. Acad. Sci. USA* 2017, *114*, E11121–E11130; b) J. S. Bauer, S. Fillinger, K. Förstner, A. Herbig, A. C. Jones, K. Flinspach, C. Sharma, H. Gross, K. Nieselt, A. K. Apel, *RNA Biol.* 2017, *14*, 1617–1626.

Manuscript received: September 17, 2019 Revised manuscript received: October 24, 2019 Accepted manuscript online: November 6, 2019 Version of record online: December 2, 2019

1148 www.angewandte.org



Supporting Information

Searching for Small Molecules with an Atomic Sort

Brendan M. Duggan,* Reiko Cullum, William Fenical, Luis A. Amador, Abimael D. Rodríguez, and James J. La Clair*

anie_201911862_sm_miscellaneous_information.pdf

Contents:	Page
Materials, methods and experimental procedures	S3-S4
 Table S1. Atomic novelty scores for bromophycolide A Table S2. Atomic novelty scores for strychnine Table S3. Atomic novelty scores for brusatol Table S4. Atomic novelty scores for paclitaxel Table S5. Atomic novelty scores for the CNB-982 extract Table S6. Atomic novelty scores for cyclomarin A Table S7. NMR spectral data for cyclomarin A in CD₃OD Table S8. Atomic novelty scores for gracilioether L Table S10. NMR spectral data for gracilioether L in CD₃OD 	S5 S6 S7 S8 S9-15 S16-17 S18-19 S20-24 S25 S26
Figure S1. Peak comparative analyses for cyclomarin A Figure S2. Peak comparative analyses for gracilioether L Figure S3. Peak shift analyses for cyclomarin A Figure S4. Structure elucidation of gracilioether L Figure S5. ¹ H- ¹³ C HSQC database (Fig. 1c) Figure S6. ¹ H- ¹³ C HSQC database (Fig. 1c) Figure S7. Profiled spectrum of bromophycolide A in CD ₃ OD (Fig. 1a) Figure S8. ¹ H- ¹³ C HSQC spectrum of strychnine in CDCl ₃ Figure S9. Profiled spectrum of strychnine Figure S10. ¹ H- ¹³ C HSQC spectrum of brusatol in CD ₃ OD Figure S11. Profiled spectrum of brusatol Figure S12. ¹ H- ¹³ C HSQC spectrum of paclitaxel in CD ₃ OD Figure S13. Profiled spectrum of paclitaxel Figure S14. ¹ H- ¹³ C HSQC spectrum of the CNB-982 extract Figure S15. Profiled spectrum of the CNB-982 extract Figure S16. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S17. Profiled spectrum of cyclomarin A in CD ₃ OD Figure S18. ¹ H NMR spectrum of cyclomarin A in CD ₃ OD Figure S19. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S19. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S19. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S19. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S19. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S19. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S19. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S20. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S20. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S20. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S20. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S20. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S20. ¹ H- ¹³ C HSQC spectrum of cyclomarin A in CD ₃ OD Figure S20. ¹ H. ¹³ C HSQC spectrum of cyclomarin A in CD ₁ OD	S27 S28 S29 S30 S31 S32 S33 S34 S35 S36 S37 S38 S39 S40 S41 S42 S43 S44 S45 S46 S47 S48
Figure S23. ¹ H- ¹³ C HSQC spectrum of the IM06-19 extract Figure S24. Profiled spectrum of the IM06-19 extract Figure S25. ¹ H- ¹³ C HSQC spectrum of gracilioether L Figure S26. Profiled spectrum of gracilioether L Figure S27. ¹ H NMR spectrum of gracilioether L in CD ₃ OD Figure S28. ¹ H- ¹ H gCOSY spectrum of gracilioether L in CD ₃ OD Figure S29. ¹ H- ¹ H NOESY spectrum of gracilioether L in CD ₃ OD Figure S30. ¹ H- ¹³ C HMBC spectrum of gracilioether L in CD ₃ OD	S49 S50 S51 S52 S53 S54 S55 S56

A. General Experimental Procedures. Chemical reagents were purchased from Acros. Fluka. Sigma-Aldrich, or TCI. Deuterated NMR solvents were purchased from Cambridge Isotope Laboratories. Analytical Thin Layer Chromatography (TLC) was performed on Silica Gel 60 F254 precoated glass plates (EM Sciences). Preparative TLC (pTLC) was conducted on Silica Gel 60 plates (EM Sciences). Visualization was achieved with UV light and/or an appropriate stain (I₂ on SiO₂, KMnO₄, bromocresol green, dinitrophenylhydrazine, ninhydrin, and ceric ammonium molybdate). Flash chromatography was carried out on Geduran Silica Gel 60 (40-63 mesh) from Analtech or EM Biosciences. Analytical HPLC was carried out using a HarmonySecure RP18 (250 x 4.6 mm i.d., 5 µm) column and was performed on an Agilent 1260 series system controller provided with an Agilent 1260 G1315D photodiode array detector with ChemStation software (Agilent). Optical rotations were measured in CHCI₃ with an Autopol IV automatic Polarimeter using a 10 mm microcell. Infrared and UV spectra were recorded using a Bruker Tensor 27 FTIR spectrometer and a Shimadzu UV-2401 PC UV-VIS recording spectrophotometer, respectively. NMR data were acquired with a Bruker DRX-500 spectrometer, Varian VS500 spectrometer, Varian VX500 spectrometer equipped with a Xsens Cold probe or a Bruker Avance III 600 equipped with a 1.7mm cryoprobe. Chemical shifts were referenced using the corresponding solvent signals ($\delta_{\rm H}$ 7.26 and $\delta_{\rm C}$ 77.00 for CDCl₃, $\delta_{\rm H}$ 3.31 and $\delta_{\rm C}$ 49.0 for CD₃OD). The NMR spectra were processed using Mestrenova (Mnova 11.0 Mestrelab Research) or TopSpin 3.0 (Bruker Biospin) software.

B. Microbial culturing. Strain CNB-382 was initially cultured in a 1 L volume using a seawater based A1 medium composed of 6 g of starch, 4 g of yeast, 2 g of glucose, 2 g of peptone, and 1 L seawater. After 7 days of cultivation, the broth was extracted with 1 L EtOAc, and the solvent was removed under vacuum to yield 30 mg of organic extract.

C. Purification of cyclomarin **A.** The organic extract (30 mg) was subjected to size exclusion chromatography (Sephadex LH-20) eluting with MeOH. Fractions containing cyclomarin A, as determined by NMR data, were then collected and fractionated by C-18 reversed-phase semi-prep HPLC (Phenomenex Luna C-18 column, 250 × 10 mm column, 5 μ m; 3 mL/min; 35% for 10 min and increase to 100% MeCN/H₂O over 60 min; UV detection at 210 nm) to yield cyclomarin A (1.8 mg).

Cyclomarin A. Colorless oil; $[\alpha]_D^{20} = -51.7^{\circ}$ (*c* 0.48, CHCl₃); UV (MeOH) λ_{max} 222 (22,900), 287 (1000), and 293 (11,200); IR *v* (neat) 3400-3300, 3030, 2962, 2928, 2871, 1644, 1512, 1453, and 748 cm⁻¹; 1D and 2D-NMR data provided in Table S7; HR-FABMS obsd. [M]⁺ *m/z* 1025.6062, calcd. 1025.6057 for C₅₆H₈₀O₁₀N₉; EI-MS (% relative intensity) 814 (1), 731 (1), 459 (2), 368 (3), 313 (4), 282 (16), 229 (35), 186 (21), 144 (69), 121 (100), and 116 (33).

D. Animal Material. The sponge *Plakortis halichondrioides* was collected in June 2006 during an underwater expedition near Mona Island, Puerto Rico. The sponge was frozen at -20 °C, and then lyophilized. A voucher specimen (IM06-19) is stored at the Molecular Sciences Research Center, University of Puerto Rico.

E. Purification of gracilioether L. The dry sponge *Plakortis halichondrioides* (32.4 g dry weight) was carefully cut into small chunks and blended in 1:1 CHCl₃/MeOH (2 × 100 L) at rt. After filtration, the crude extract was *concentrated in vacuo* to yield a brown thick paste (1.9 g). This extract was presented to flash column (38 mm ID × 200 mm height) washing with six rows of 15 test tubes with 150 mL of solvent (10 mL/tube) as given by row 1 (hexanes), row 2 (8:1 hexanes/EtOAc), row3 (4:1 hexanes/EtOAc), row 4 (2:1 hexanes/EtOAc), row 5 (1:1 hexanes/EtOAc) and row 6 (EtOAc). Each tube was explored by TLC analysis and tube 10 in row 5 displayed the targeted peaks. This was then subjected twice to pTLC first with 1:1 hexanes/EtOAc then 1:1 hexanes/acetone to deliver 1.2 mg of gracilioether L.

Gracilioether L. Colorless oil; $[α]_D^{20}$ = -89.2 (*c* 0.05, CH₃OH); UV (CH₃OH) $λ_{max}$ (log ε) 286 (2.74), 243 (2.17), 205 (2.42) nm; 1D and 2D-NMR data provided in Table S11; HR-ESI-MS *m/z* calcd. for C₂₁H₃₂O₄ [M+Na]⁺: *m/z* 371.2198, found 371.2193.

F. HSQC database. Publicly available ¹H-¹³C HSQC spectra were downloaded from HMDB (ww.hmdb.ca) and BMRB (bmrb.wisc.edu/metabolomics). Chemical shift referencing of the spectra was not modified after downloading. Chemical shifts were extracted from the peak lists in the downloaded data using perl and shell scripts and used without further modification. Precision of the chemical shifts varies depending on the data source. Plotting the chemical shift data enabled visual identification of outliers, which were inspected manually using TopSpin. Peaks picked on noise, artifacts, or two bond correlations were removed. Chemical shifts for common solvents were obtained from Tables 1 and 2 in Gottlieb, H. E.; Kotyar, V.W.; Nudelman, A. J. Org. Chem. 1997, 62, 7512-7515. In-house ¹H-¹³C HSQC spectra of standards cholesteryl acetate, sucrose, o-dichlorobenzene, ethylbenzene, strychnine and streptomycin and from recent projects (see references: (a) Mehrotra S.; Duggan, B. M. Tello-Aburto, R.; Newar, T. D.; Gerwick, W. H.; Murray, T. F.; Maio, W. A. J. Nat Prod. 2014, 77, 2553-2260; (b) Kleigrewe, K.; Almaliti, J.; Tian, I. Y.; Kinnel, R. B.; Korobeynikov, A.; Monroe, E. A.; Duggan, B. M.; Di Marzo, V.; Sherman, D. H.; Dorrestein, P. C.; Gerwick, L.; Gerwick, W. H. J. Nat. Prod. 2015, 78, 1671-1682; (c) Wang, X.; Duggan, B. M., Molinski, T. F. J. Am. Chem. Soc. 2015, 137, 12343-12351; (d) White, A. R.; Duggan, B. M.; Tsai, S. C.; Vanderwal, C. D. Org Lett. **2016**, *18*, 1124-1127; (e) Carling, C. J.; Olejniczak, J.; Foucault-Collet, A.; Collet, G.; Viger, M. L.; Huu, V. A.; Duggan, B. M.; Almutairi, A. Chem. Sci. 2016, 7, 2392-2398; (f) Li, Z. R.; Li, J.; Gu, J. P.; Lai, J. Y.; Duggan, B. M.; Zhang, W. P.; Li, Z. L.; Li, Y. X.; Tong, R. B.; Xu, Y.; Lin, D. H.; Moore, B. S.; Qian, P. Y. Nat. Chem. Biol. 2016, 12, 773-775) were processed with TopSpin 3.6. Spectra were referenced to internal TMS or residual solvent. Peaks were picked automatically at a high threshold with the interpolation type set to "parabolic". The threshold was then reduced and additional weak peaks were added. Noise, artifacts and two bond correlations were removed. Peaks picked on individual lines in multiplets were combined to a single peak. Peaks from all four data sources were combined to give the final database. A subset of the database that excluded aldehydes was fitted to a straight line to obtain the equation δ_c = 16.9989 $\delta_{\rm H}$ + 1.06803. Including aldehydes gave a poor fit. Taking every point in the database the difference between the experimental δ_c and that calculated from the fitted line was determined and the standard deviation of these differences calculated. In the entire database only six points were found to fall more than four standard deviations (99.99% confidence limit) from the line.

G. Chemical shift extraction and distance scoring. Samples for profiling were dissolved in 50μ I of methanol-d₄ and transferred to 1.7mm NMR tubes. ¹H-¹³C HSQC spectra were collected using a 1.7mm microcryoprobe and processed using TopSpin 3.6. Peaks were picked as described above for the database spectra. Peaks more than four standard deviations from the line fitted to the database were flagged. The distance score was calculated as

distance score = { [
$$(\delta_{H,query}, \delta_{H,db})$$
 / range δ_{H}]² + [$(\delta_{C,query}, \delta_{C,db})$ / range δ_{C}]² }^{1/2}

where δ_H is the proton chemical shift, δ_c is the carbon chemical shift, the subscript "query" indicates the query peak and "db" a peak in the database, and range is the difference between the minimum and maximum chemical shifts of the indicated nucleus observed in the database. For each query peak the distance score was calculated for all peaks in the database and the minimum value reported.

Table S1. Atomic novelty scores for bromophycolide A



peak ¹	position ²	δ _H	δ _c	distance
14	14	4.69	81.4	0.47%
16	22	4.56	61.8	0.36%
1	3	7.99	132.1	0.35%
12	16	7.74	130.2	0.25%
18	5	3.47	30.0	0.25%
19	20	2.07	34.0	0.23%
5	12	1.17	36.1	0.20%
13	17	6.88	115.4	0.20%
3	8	1.93	38.8	0.19%
21	21	2.32	31.4	0.15%
4	9	1.80	29.5	0.14%
23	9	2.08	29.4	0.13%
17	5	3.30	30.0	0.12%
11	24	1.30	26.2	0.12%
7	27	1.81	31.7	0.12%
8	23	1.42	20.9	0.09%
2	12	1.64	36.1	0.08%
10	26	1.83	31.0	0.07%
6	8	1.36	38.8	0.06%
15	10	3.40	72.3	0.03%
9	25	1.28	33.2	0.02%
20	20	2.35	34.0	0.02%
22	13	2.12	29.3	0.02%

¹ Peak is a number that identifies the order that the peaks were abstracted from the raw data.

² Position identifies the atom number given by Kubanek, J.; Prusak, A. C.; Snell, T. W.; Giese, R. A.; Hardcastle, K. I.; Fairchild, C. R.; Aalbersberg, W.; Raventos-Suarez, C.; Hay, M. E. *Org. Lett.* **2005**, *7*, 5261-5264.

Table S2. Atomic novelty scores for strychnine



peak ¹	position ²	δ _H	δ _c	distance ³
2	4	8.10	116.3	1.89%
14	13	1.27	48.2	1.01%
3	22	5.90	127.4	0.60%
6	20	2.72	52.6	0.49%
7	20	3.70	52.6	0.43%
19	12	4.28	77.6	0.42%
12	18	3.20	50.4	0.37%
16	17	1.89	42.8	0.37%
21	16	3.95	60.2	0.30%
15	14	3.14	31.6	0.29%
9	15	2.37	27.0	0.27%
20	8	3.85	60.1	0.26%
13	18	2.87	50.4	0.26%
8	11	2.65	42.5	0.17%
17	23	4.07	64.5	0.15%
11	11	3.11	42.4	0.15%
18	23	4.14	64.6	0.13%
1	3	7.26	128.5	0.12%
10	15	1.47	26.8	0.08%
5	1	7.16	122.4	0.07%
4	2	7.10	124.2	0.03%

¹ Peak is a number that identifies the order that the peaks were abstracted from the raw data.

² Position identifies the atom number as given by Verpoorte R. *J. Pharm Sci.* **1980**, 69, 865-866.

³ The strychnine data was removed from the database before calculating these distance scores.

Table S3. Atomic novelty scores for brusatol



peak ¹	position ²	δ _H	δ _c	distance
2	7	4.91	84.5	0.91%
11	19	1.84	13.1	0.54%
9	28	2.17	20.2	0.53%
16	1	2.84	49.8	0.35%
17	1	2.53	49.8	0.33%
18	6	2.30	29.7	0.30%
15	5	2.97	42.9	0.26%
5	14	3.80	52.8	0.21%
4	11,15	4.17	72.6	0.16%
10	27	1.94	27.2	0.12%
13	20	4.69	74.2	0.08%
14	20	3.71	74.2	0.07%
8	6	1.87	29.8	0.07%
12	18	1.37	15.3	0.07%
3	25	5.68	115.6	0.05%
1	12	4.20	76.2	0.05%
6	23	3.72	52.7	0.03%
19	9	2.21	42.1	0.02%

¹ Peak is a number that identifies the order that the peaks were abstracted from the raw data.

² Position identifies the atom number as given by Hagigaya, Y.; Konda, Y.; Iguchi, M.; Onda, M.; Li, X.; Wu, L.; Li, S.; Sun, X. *J. Nat. Prod.* **1989**, *52*, 740-748.

Table S4. Atomic novelty scores for paclitaxel



peak ¹	position ²	δ _H	δ _c	distance
14	10	6.45	76.5	1.76%
12	32	5.64	57.5	1.73%
11	13	6.16	71.9	1.12%
27	5	5.00	85.6	0.65%
19	29	2.17	20.5	0.48%
26	2	5.65	75.9	0.46%
20	27	2.36	22.9	0.37%
28	3	3.83	47.6	0.36%
21	19	1.66	10.1	0.31%
8	21,25	8.11	130.9	0.24%
1	23	7.67	134.3	0.19%
7	34,38	7.49	128.2	0.18%
5	41,43	7.47	129.3	0.18%
3	42	7.55	132.6	0.17%
2	36	7.29	128.7	0.16%
15	27	4.19	77.2	0.15%
22	6	2.47	37.2	0.14%
16	16	1.15	22.0	0.14%
6	35, 37	7.42	129.4	0.13%
9	40, 44	7.86	128.2	0.13%
4	22, 24	7.58	129.4	0.10%
13	31	4.74	74.6	0.07%
18	18	1.91	14.4	0.06%
24	6	1.81	37.2	0.03%
17	17	1.16	26.6	0.03%
25	14	1.96	36.2	0.02%
23	14	2.23	36.3	0.01%
10	7	4.32	72.0	0.01%

¹ Peak is a number that identifies the order that the peaks were abstracted from the raw data.

² Position identifies the atom number as given by Chmurny, G. N.; Hilton, B. D.; Brobst, S.; Look, S. A.; Witherup, K. M.; Beutler, J. A. *J. Nat. Prod.* **1982**, *55*, 414-423.

peak ²	δ _Η	δ _c	distance
289	-0.91	32.4	13.74%
95	6.15	145.4	2.53%
94	5.97	147.4	2.36%
2	7.27	147.9	2.01%
270	0.80	3.9	1.91%
192	2.58	67.9	1.60%
146	5.33	89.5	1.51%
191	2.70	67.9	1.42%
7	8.23	134.0	1.36%
6	8.22	122.4	1.28%
259	0.75	7.6	1.28%
60	0.34	15.4	1.28%
194	2.97	67.6	1.15%
274	1.05	42.5	1.14%
260	0.85	5.0	1.13%
287	5.33	59.9	1.13%
271	0.77	7.8	1.11%
137	5.11	126.6	1.10%
203	2.62	25.4	1.00%
58	4.93	84.4	1.00%
288	5.03	126.2	0.98%
275	1.10	42.0	0.97%
122	7.79	114.3	0.95%
9	6.61	98.0	0.90%
280	4.72	95.1	0.89%
149	4.59	64.5	0.73%
40	5.00	57.3	0.71%
139	5.21	113.7	0.71%
181	4.01	45.0	0.71%
151	4.54	57.1	0.69%
43	4.74	66.0	0.69%
145	5.26	70.9	0.66%
272	0.42	16.7	0.66%
169	3.25	78.5	0.64%
134	6.88	110.6	0.63%
91	5.12	77.9	0.60%
190	3.60	46.1	0.59%
193	2.91	67.6	0.56%
143	5.20	76.7	0.56%
142	5.26	73.7	0.55%
153	4.35	54.9	0.54%
170	3.24	80.9	0.50%

 Table S5. Atomic novelty scores for the CNB-982 extract.1

183	4.02	51.4	0.50%
97	6.64	131.6	0.49%
261	1.00	6.9	0.48%
158	3.94	54.1	0.47%
176	3.39	43.2	0.47%
35	4.53	59.1	0.47%
140	5.00	76.8	0.46%
157	3.91	60.5	0.46%
215	1.68	43.4	0.45%
232	2.01	23.3	0.45%
22	4.40	51.5	0.43%
132	6.71	111.5	0.43%
217	1.77	41.9	0.43%
279	5.02	111.7	0.43%
163	4.31	57.0	0.43%
133	6.56	111.4	0.42%
67	2.03	23.0	0.41%
104	7.04	131.9	0.41%
286	1.10	29.5	0.40%
167	4.01	84.3	0.40%
99	7.78	132.5	0.39%
29	2.04	13.8	0.39%
150	4.46	68.8	0.39%
196	2.82	45.9	0.38%
79	2.50	29.6	0.37%
189	3.42	44.3	0.36%
184	3.50	48.9	0.36%
101	8.02	130.4	0.36%
236	1.19	25.7	0.35%
266	0.92	33.7	0.35%
156	4.00	59.8	0.34%
36	3.37	45.6	0.33%
144	5.34	73.2	0.33%
177	3.37	41.9	0.33%
100	7.85	132.2	0.33%
27	2.08	22.2	0.33%
126	7.46	112.7	0.32%
221	1.27	40.5	0.32%
218	1.87	42.1	0.32%
209	2.32	31.0	0.31%
206	2.81	32.8	0.31%
257	0.96	17.6	0.31%
123	7.58	119.5	0.31%
20	1.17	28.8	0.31%

108	7.21	123.1	0.30%
49	4.06	59.8	0.29%
242	0.96	21.9	0.29%
70	2.32	29.2	0.29%
175	4.18	51.8	0.29%
72	3.54	45.8	0.28%
45	1.98	15.1	0.28%
119	7.35	126.1	0.27%
141	4.84	73.7	0.27%
103	7.91	131.3	0.27%
131	6.66	116.0	0.27%
222	1.12	40.4	0.26%
44	3.25	58.5	0.26%
246	1.14	17.3	0.26%
121	7.90	122.3	0.26%
201	2.49	39.0	0.25%
148	4.79	58.9	0.25%
211	2.06	39.3	0.25%
179	3.74	46.7	0.25%
262	0.67	16.6	0.25%
224	1.25	34.3	0.24%
216	1.68	42.6	0.24%
164	4.42	56.9	0.24%
31	1.13	24.5	0.24%
83	4.26	60.0	0.24%
52	4.60	46.7	0.23%
17	5.35	130.6	0.23%
278	2.03	42.2	0.23%
250	1.07	15.2	0.23%
225	1.23	32.9	0.23%
200	2.55	38.2	0.23%
178	3.51	43.2	0.23%
248	1.18	18.8	0.22%
159	3.90	54.5	0.22%
74	4.19	59.7	0.22%
16	7.28	130.1	0.22%
63	1.93	23.0	0.22%
208	2.30	28.8	0.22%
65	4.44	57.4	0.22%
256	1.01	15.4	0.21%
118	7.46	129.2	0.21%
82	2.88	29.9	0.21%
284	1.19	28.3	0.21%
10	7.13	122.4	0.21%

76	0.90	19.7	0.21%
152	4.65	57.9	0.21%
155	4.26	59.0	0.20%
239	1.06	22.3	0.20%
102	8.06	129.4	0.20%
129	6.75	115.7	0.20%
13	7.24	129.1	0.20%
277	1.43	38.2	0.20%
75	4.03	61.2	0.19%
172	3.54	62.7	0.19%
138	5.38	131.2	0.19%
96	6.60	134.1	0.19%
42	3.25	55.7	0.19%
204	2.77	36.5	0.19%
213	2.35	29.8	0.19%
77	1.64	19.4	0.19%
90	3.34	56.0	0.19%
173	3.59	62.1	0.19%
105	7.03	130.6	0.19%
240	1.00	20.8	0.18%
214	2.29	23.5	0.18%
212	2.05	28.8	0.18%
258	1.02	21.9	0.18%
241	0.97	20.1	0.18%
66	1.11	19.0	0.18%
1	7.22	131.3	0.18%
41	1.74	28.1	0.17%
86	4.07	61.0	0.17%
46	1.12	18.5	0.17%
81	1.68	24.7	0.17%
11	7.29	127.6	0.17%
54	2.01	28.8	0.17%
220	1.57	32.4	0.17%
26	4.36	57.6	0.17%
254	1.00	18.1	0.17%
182	4.10	46.6	0.17%
116	7.36	128.0	0.16%
180	3.83	45.0	0.16%
68	3.64	71.2	0.16%
264	1.69	16.1	0.16%
273	2.16	44.0	0.16%
263	0.86	9.9	0.16%
276	1.91	39.1	0.16%
38	1.17	25.6	0.15%

78	1.81	25.9	0.15%
223	1.18	40.0	0.15%
135	7.04	120.3	0.15%
154	4.23	57.2	0.15%
186	3.03	37.4	0.15%
28	1.91	19.9	0.14%
47	3.04	39.9	0.14%
19	1.60	26.6	0.14%
53	2.19	36.3	0.14%
109	7.23	124.1	0.14%
269	0.86	10.9	0.14%
249	1.17	19.9	0.14%
197	2.67	40.3	0.14%
107	7.01	119.7	0.14%
185	3.09	37.4	0.14%
219	1.82	42.1	0.14%
265	1.12	32.1	0.14%
5	7.10	125.3	0.14%
252	1.00	23.1	0.14%
238	1.03	23.8	0.14%
188	3.19	40.7	0.13%
136	5.77	125.1	0.13%
244	1.09	18.6	0.13%
187	2.99	40.6	0.13%
117	7.40	129.6	0.13%
127	7.33	112.0	0.13%
199	2.71	39.1	0.13%
8	7.30	128.2	0.13%
243	0.96	23.0	0.13%
147	5.18	61.2	0.13%
165	4.09	71.4	0.13%
71	1.12	19.6	0.12%
24	1.31	20.7	0.12%
115	7.18	127.0	0.12%
62	0.89	22.8	0.12%
233	1.74	25.8	0.12%
106	7.09	122.3	0.12%
21	1.35	20.7	0.12%
285	1.53	28.9	0.12%
64	1.52	39.1	0.11%
268	0.91	11.0	0.11%
33	1.44	25.1	0.11%
15	7.23	127.6	0.11%
3	7.24	130.0	0.11%

112	7.28	130.9	0.11%
229	1.68	26.2	0.11%
255	1.03	15.3	0.11%
80	4.13	54.3	0.11%
125	7.50	114.7	0.11%
227	1.52	33.3	0.11%
51	1.14	18.9	0.11%
230	1.88	25.5	0.11%
128	6.86	116.1	0.10%
210	1.98	33.3	0.10%
61	2.68	30.3	0.10%
231	1.86	25.0	0.10%
4	7.35	129.2	0.10%
195	2.88	45.9	0.10%
228	1.35	30.4	0.10%
89	3.31	49.0	0.10%
120	7.26	124.8	0.10%
162	3.78	61.2	0.10%
92	3.59	41.9	0.10%
32	1.91	22.3	0.09%
88	3.51	46.1	0.09%
198	2.75	40.1	0.09%
205	2.81	29.7	0.09%
48	2.67	37.8	0.09%
160	3.84	56.0	0.09%
237	1.14	20.9	0.09%
124	7.54	120.0	0.08%
171	3.68	64.4	0.08%
59	0.96	19.1	0.08%
37	2.03	27.9	0.08%
207	2.32	34.7	0.08%
114	7.18	131.0	0.08%
34	1.91	23.3	0.08%
18	1.32	25.1	0.08%
130	6.71	115.9	0.08%
57	1.15	18.4	0.07%
55	2.16	36.7	0.07%
30	2.09	29.1	0.07%
84	1.50	22.8	0.07%
235	1.45	20.6	0.07%
87	0.93	12.3	0.06%
12	7.26	128.9	0.06%
282	1.33	30.0	0.06%
39	1.32	23.4	0.06%

56 7	0.06%
00.7	0.00 /0
128.1	0.06%
15.4	0.06%
19.0	0.06%
126.7	0.06%
40.1	0.05%
34.8	0.05%
65.4	0.05%
72.3	0.05%
16.4	0.05%
29.1	0.05%
29.2	0.05%
72.6	0.04%
17.8	0.04%
30.5	0.04%
31.5	0.04%
130.8	0.03%
19.9	0.03%
124.6	0.03%
32.8	0.03%
22.5	0.03%
58.1	0.03%
37.9	0.02%
64.0	0.02%
14.3	0.01%
129.2	0.01%
25.0	0.01%
	128.1 15.4 19.0 126.7 40.1 34.8 65.4 72.3 16.4 29.1 29.2 72.6 17.8 30.5 31.5 130.8 19.9 124.6 32.8 22.5 58.1 37.9 64.0 14.3 129.2

¹ Green shading denotes the top five peaks observed in the pure cyclomarin A spectrum (Table S6). These peaks were identified after the pure material was obtained to emphasize that many of the most highly scoring peaks in the mixture came from a single compound, namely cyclomarin A.

² Peak is a number that identifies the order that the peaks were abstracted from the raw data.

Table S6. Atomic novelty scores for cyclomarin A



peak ¹	position ²	δ _Η	δ _c	distance
41	51β	-0.92	32.4	13.64%
7	53β	2.58	67.9	1.62%
34	53α	2.71	67.9	1.37%
12	54	0.35	15.6	1.24%
29	26	5.34	61.7	1.18%
27	20	5.03	126.3	0.99%
4	38	4.97	84.5	0.99%
25	7	7.79	114.3	0.91%
32	32	4.54	57.1	0.69%
28	3	5.26	70.8	0.64%
6	37	4.99	57.4	0.62%
31	18	4.52	59.1	0.54%
33	47	4.39	51.4	0.43%
20	NMe-8	2.50	27.7	0.39%
36	33	2.31	31.1	0.36%
13	14β	2.83	46.1	0.36%
24	10	7.91	122.5	0.29%
15	13	3.25	58.5	0.26%
11	29	1.07	22.4	0.23%
30	50	4.79	58.0	0.22%
40	52	1.23	33.1	0.20%
18	NMe-4	2.88	28.1	0.20%
5	2	4.65	58.0	0.19%
1	8	7.13	122.3	0.19%
45	23	1.61	22.7	0.18%
22	15	1.69	24.8	0.17%

2	9	7.04	120.2	0.17%
16	34	0.98	20.1	0.15%
19	22	1.81	26.0	0.15%
38	48	1.00	20.8	0.15%
37	35	1.12	19.5	0.13%
14	19	2.77	36.6	0.13%
17	30	1.04	23.9	0.11%
23	16	1.50	22.7	0.11%
43	41,43	7.29	129.3	0.09%
9	27β	1.14	40.1	0.08%
26	40,44	7.32	128.0	0.07%
10	27α	2.44	40.1	0.07%
35	14α	2.89	46.1	0.06%
8	51α	1.57	32.4	0.06%
44	28	1.77	24.9	0.05%
39	24	0.96	19.1	0.04%
21	45	3.22	58.1	0.04%
3	4	7.21	124.8	0.03%
42	42	7.26	129.1	0.02%

¹ Peak is a number that identifies the order that the peaks were abstracted from the raw data.

² Position identifies the atom number as given in Renner, M. K.; Shen, Y.-C.; Cheng, X.-C.; Jensen, P. R.; Frankmolle, W.; Kaufmann, C. A.; Fenical, W.; Lobkovsky, E.; Clardy, J. *J. Am. Chem. Soc.* **1999**, *121*, 11273-11276.

Table S7. NMR spectral data for cyclomarin A in CD₃OD



cyclomarin A

Position	δ_C , Type	δ _H , mult (<i>J</i> in Hz)	¹ H- ¹ H COSY	¹ H- ¹³ C HMBC ¹
1	171.8, C	-		
2	58.0,CH	4.65, d (9.3)	3	1,3,5,17
3	70.8,CH	5.26, d (9.3)	2	2,4,5,6
4	124.8,CH	7.21 s		2,3,5,6,10w,11
5	114.3,C	-		
6	127.5,C	-		
7	122.5, CH	7.91 d (7.9)	8	6,9
8	122.3,CH	7.13, t (7.5)	7,9	7w,10,11
9	120.2, CH	7.04, t (7.6)	8,10	6,7
10	114.3,CH	7.79, d (8.5)	9	7,8,11
11	135.2, C	-		
12	57.4,C	-		
13	58.5,CH	3.25 dd (2.6, 4.1)	14α,14β	14
14α	46 1 CH ₂	2.89 m	13,14β	13
14β	10.1,0112	2.83 dd (2.7, 4.7)	13,14α	
15	24.8,CH ₃	1.69 s	16	
16	22.7,CH ₃	1.50 s	15	
17	172.3,C	-		
18	59.1,CH	4.52 d (10.0)	19	17,19,20,25
19	36.6,CH	2.77 dt (6.5,10.2)	18,20,24	17,18,20,21
20	126.3,CH	5.03 d (9.8)	19,22,23	18,19,22,23
21	134.5,C	-		
22	26.0,CH ₃	1.81 d (0.4)	20	20,21,23
23	22.7,CH ₃	1.61 d (0.3)	20	20,21,22
24	19.1,CH ₃	0.96 d (6.7)	19	18,19,21
25	170.0,C	-		

61.7,CH	5.34 dd (3.0,11.3)	27α,27β	23,25,27α,27β,31,NMe-4
40 1 CH ₂	2.44 ddd (4.0, 11.3, 13.1)	26,27β,28	26,28,29,30
	1.14 m	26,27α,28	26,28,29,30
24.9,CH	1.77 m	27α,27β,29,30	26,27α,27β,29,30
22.4,CH ₃	1.07 d (6.6)	28	23,27,30
23.9,CH ₃	1.04 d (6.6)	28	23,27,29
173.2,C	-		
57.1,CH	4.54 d (9.5)	33	31,33,34,36
31.1,CH	2.31 ddt (13.3, 10.1, 6.7)	32,34,35	32,35
20.1,CH ₃	0.98 (d, 6.7)	33	32,33,35
19.5,CH ₃	1.12 (d, 6.6)	33	32,33,34
171.6,C	-		
57.4,CH	4.99 d (3.4)	38	36,38,45w,46
84.5,CH	4.97 d (3.6)	37	36,37,39,40,44
137.5	-		
128.0,CH	7.32 d (6.5)	41	38,44
129.3,CH	7.29 t (6.6)	40,42	39,40
129.1,CH	7.26 t (6.8)	41,43	39,40,44
129.3,CH	7.29 t (6.6)	42,44	39,44
128.0,CH	7.32 d (6.5)	43	38,40
58.1, CH₃	3.22 s		38
172.7,C	-		
51.4, CH	4.39 q (7.2)	48	46,48,49
20.8, CH ₃	1.00 d (7.2)	47	46,47
170.7,C	-		
58.0,CH	4.79 dd (2.8, 12.4)	51α,51β	1,49,52,NMe-8
32 4 CH ₂	1.57 m	50,51β,52	49,50
0211,0112	-0.92 m	50,51α,52	49,50,NMe-8
33.1,CH	1.23 m	51α,51β,54,53	54
67.9.CH ₂	2.71 dd (6.1, 10.6)	52,53β	52,54
·····	2.58 dd (7.3, 10.6)	52,53α	52,54
15.6,CH ₃	0.35 d (6.7)	52	51,52,54
28.1,CH ₃	2.88 s		26,31
27.7,CH ₃	2.50 s		1,3w,50
	61.7,CH 40.1,CH ₂ 24.9,CH 22.4,CH ₃ 23.9,CH ₃ 173.2,C 57.1,CH 31.1,CH 20.1,CH ₃ 19.5,CH ₃ 171.6,C 57.4,CH 84.5,CH 137.5 128.0,CH 129.3,CH 129.3,CH 129.3,CH 129.3,CH 129.3,CH 129.3,CH 129.3,CH 129.3,CH 129.3,CH 128.0,CH 32.4,CH ₂ 33.1,CH 67.9,CH ₂ 15.6,CH ₃ 28.1,CH ₃ 27.7,CH ₃	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{ccccc} 61.7, CH & 5.34 \mbox{ d} (3.0, 11.3) & 27 \alpha, 27 \beta \\ \hline 40.1, CH_2 & 2.44 \mbox{ dd} (4.0, 11.3, 13.1) & 26, 27 \beta, 28 \\ \hline 1.14 \mbox{ m} & 26, 27 \alpha, 28 \\ \hline 24.9, CH & 1.77 \mbox{ m} & 27 \alpha, 27 \beta, 29, 30 \\ \hline 22.4, CH_3 & 1.07 \mbox{ d} (6.6) & 28 \\ \hline 23.9, CH_3 & 1.04 \mbox{ d} (6.6) & 28 \\ \hline 173.2, C & - & & \\ \hline 57.1, CH & 4.54 \mbox{ d} (9.5) & 33 \\ \hline 31.1, CH & 2.31 \mbox{ dt} (13.3, 10.1, 6.7) & 32, 34, 35 \\ \hline 20.1, CH_3 & 0.98 \mbox{ (d}, 6.7) & 33 \\ \hline 19.5, CH_3 & 1.12 \mbox{ (d}, 6.6) & 33 \\ \hline 19.5, CH_3 & 1.12 \mbox{ (d}, 6.6) & 33 \\ \hline 171.6, C & - & & \\ \hline 57.4, CH & 4.99 \mbox{ d} (3.4) & 38 \\ \hline 84.5, CH & 4.97 \mbox{ d} (3.6) & 37 \\ \hline 137.5 & - & & \\ \hline 128.0, CH & 7.32 \mbox{ d} (6.5) & 41 \\ \hline 129.3, CH & 7.29 \mbox{ t} (6.6) & 40, 42 \\ \hline 129.1, CH & 7.26 \mbox{ t} (6.8) & 41, 43 \\ \hline 129.3, CH & 7.29 \mbox{ t} (6.6) & 42, 44 \\ \hline 128.0, CH & 7.32 \mbox{ d} (6.5) & 43 \\ \hline 58.1, CH_3 & 3.22 \mbox{ s} & \\ \hline 172.7, C & - & \\ \hline 51.4, CH & 4.39 \mbox{ q} (7.2) & 48 \\ \hline 20.8, CH_3 & 1.00 \mbox{ d} (7.2) & 47 \\ \hline 170.7, C & - & \\ \hline 58.0, CH & 4.79 \mbox{ d} (2.8, 12.4) & 51 \mbox{ s} 1\beta, 52 \\ \hline -0.92 \mbox{ m} & 50, 51 \mbox{ s} 52 \\ \hline 33.1, CH & 1.23 \mbox{ m} & 51 \mbox{ s} 1\beta, 54, 53 \\ \hline 67.9, CH_2 & & \\ \hline 28.1, CH_3 & 2.88 \mbox{ s} & \\ \hline 27.7, CH_3 & 2.50 \mbox{ s} & \\ \hline \end{array}$

¹ w denotes a weak cross peak

peak ²	δ _Η	δ _c	distance
159	6.43	148.3	3.30%
1	6.68	154.9	3.13%
153	5.03	134.5	1.62%
3	5.08	134.7	1.19%
152	6.48	142.2	1.13%
161	5.55	125.7	1.09%
146	0.80	8.1	0.93%
169	5.32	135.2	0.87%
86	0.84	29.5	0.85%
165	5.36	133.6	0.79%
13	3.66	51.1	0.75%
141	0.85	8.0	0.66%
5	4.58	78.1	0.63%
163	5.04	125.4	0.63%
4	5.42	133.7	0.61%
151	7.13	153.2	0.53%
68	1.75	39.1	0.47%
95	0.83	9.0	0.43%
8	4.85	83.9	0.42%
104	0.96	8.1	0.40%
160	6.24	129.8	0.39%
157	5.16	73.0	0.38%
66	0.87	33.9	0.38%
154	4.51	78.7	0.38%
113	1.18	21.9	0.37%
166	5.35	130.9	0.36%
176	1.86	45.6	0.35%
122	1.23	34.6	0.34%
188	1.63	34.1	0.34%
175	1.75	45.8	0.33%
186	1.89	43.8	0.33%
124	1.57	33.9	0.33%
144	1.18	12.6	0.32%
100	0.96	13.1	0.31%
14	2.13	45.9	0.31%
69	0.96	10.5	0.30%
106	1.09	12.3	0.30%
2	6.06	132.4	0.29%
136	2.27	19.5	0.29%
21	1.26	35.8	0.29%
61	1.27	36.7	0.28%
36	0.96	9.7	0.28%

Table S8. Tabulation of the atomic novelty scores for the IM06-19 extract¹

35	1.03	12.2	0.28%
116	0.88	9.2	0.27%
102	1.22	40.1	0.26%
96	0.94	26.2	0.26%
182	1.54	41.3	0.26%
184	1.83	42.0	0.26%
173	3.70	52.2	0.26%
183	1.62	41.9	0.25%
67	0.83	22.1	0.23%
105	2.08	24.3	0.23%
115	1.21	22.3	0.23%
50	0.82	9.7	0.23%
17	2.00	37.4	0.23%
148	0.98	14.7	0.23%
180	2.48	38.3	0.22%
125	1.19	26.2	0.22%
46	1.12	38.2	0.22%
158	4.53	63.7	0.22%
37	1.69	37.9	0.22%
19	0.97	20.6	0.22%
133	1.19	29.5	0.21%
30	1.58	31.9	0.21%
71	1.24	36.3	0.21%
89	0.86	13.1	0.20%
83	1.53	25.7	0.20%
81	1.29	35.0	0.20%
70	1.01	10.3	0.20%
88	1.45	37.3	0.20%
15	1.80	45.8	0.20%
84	1.54	32.9	0.19%
187	1.69	38.8	0.19%
177	2.31	41.7	0.19%
123	2.92	32.3	0.19%
192	1.60	30.8	0.18%
194	1.38	22.0	0.18%
57	2.33	35.1	0.18%
7	4.07	83.5	0.18%
185	1.84	43.1	0.17%
49	1.03	19.9	0.17%
193	1.26	25.2	0.17%
178	2.24	37.3	0.17%
120	0.99	13.7	0.17%
12	2.89	45.4	0.17%
168	5.37	131.3	0.16%

80	2.30	21.2	0.16%
107	1.21	24.1	0.15%
98	1.80	39.0	0.15%
9	4.42	80.2	0.15%
72	0.88	21.4	0.15%
47	1.30	23.2	0.15%
78	1.84	38.8	0.15%
170	3.64	67.4	0.15%
20	1.51	26.6	0.15%
118	0.87	20.2	0.14%
42	1.47	35.6	0.14%
145	2.02	26.7	0.14%
56	1.00	9.1	0.14%
138	2.26	26.9	0.14%
55	0.89	22.1	0.14%
65	1.49	27.4	0.14%
121	1.34	36.7	0.14%
44	1.21	23.5	0.13%
16	1.50	36.1	0.13%
11	3.23	54.7	0.13%
156	4.24	70.3	0.13%
147	0.94	11.4	0.13%
140	0.88	23.0	0.13%
60	2.09	28.4	0.13%
26	0.74	12.6	0.13%
94	1.25	40.1	0.13%
93	1.81	37.8	0.12%
128	1.26	30.1	0.11%
181	2.69	37.4	0.11%
63	1.17	40.4	0.11%
45	0.83	13.0	0.11%
23	1.48	29.3	0.11%
129	1.81	31.1	0.11%
73	1.93	32.9	0.11%
58	2.04	37.5	0.11%
103	1.38	36.8	0.11%
126	1.26	26.2	0.11%
162	5.05	123.9	0.11%
39	1.68	26.1	0.11%
111	1.38	28.4	0.11%
77	1.00	17.2	0.10%
76	1.33	21.3	0.10%
134	1.27	33.9	0.10%
92	1.78	38.1	0.10%
-	-	. –	

40	1.02	11.3	0.10%
191	1.74	31.0	0.10%
32	1.05	11.3	0.10%
38	1.34	35.1	0.10%
41	1.44	26.7	0.10%
79	1.26	29.1	0.10%
6	4.21	69.4	0.10%
196	0.91	12.2	0.10%
108	0.93	13.3	0.10%
33	0.81	19.7	0.10%
85	1.14	22.4	0.10%
53	2.09	27.5	0.10%
52	1.54	30.8	0.09%
132	1.31	27.0	0.09%
135	1.38	29.5	0.09%
31	1.19	28.8	0.09%
127	1.79	32.0	0.08%
117	1.31	28.3	0.08%
64	1.30	38.3	0.08%
28	1.21	25.2	0.08%
190	2.03	25.8	0.08%
109	1.46	30.7	0.08%
43	1.25	32.9	0.08%
143	0.91	14.5	0.08%
59	1.30	21.7	0.08%
22	1.53	35.5	0.07%
27	1.10	25.3	0.07%
179	2.39	38.1	0.07%
155	4.17	71.7	0.07%
142	0.86	11.2	0.07%
195	1.04	13.1	0.07%
90	2.04	28.2	0.07%
139	2.21	19.5	0.06%
74	1.74	27.5	0.06%
164	5.44	136.0	0.06%
167	5.36	130.1	0.06%
114	1.24	22.0	0.06%
34	2.47	36.6	0.06%
112	1.60	26.1	0.06%
131	1.84	32.0	0.05%
110	1.01	8.1	0.05%
119	1.20	36.9	0.05%
25	2.41	37.3	0.05%
62	1.31	25.2	0.05%

48	1.19	30.5	0.05%
91	1.29	33.1	0.05%
97	1.16	36.4	0.05%
130	1.30	24.2	0.05%
82	0.95	9.0	0.04%
137	2.16	35.8	0.04%
149	0.84	12.2	0.03%
171	3.46	72.6	0.03%
29	1.03	21.5	0.03%
189	2.40	32.3	0.03%
172	4.27	60.5	0.03%
87	0.89	10.3	0.03%
10	3.13	47.5	0.03%
24	1.26	32.0	0.03%
174	2.47	42.9	0.03%
150	1.30	30.8	0.02%
18	0.81	10.3	0.02%
54	1.38	35.6	0.02%
75	1.73	38.2	0.02%
101	1.54	28.4	0.01%
51	1.32	22.3	0.01%
99	2.28	35.0	0.01%

¹ Green shading denotes the top four peaks observed in the pure gracilioether L spectrum (Table S9). These peaks were identified after the pure material was obtained to emphasize that many of the high scoring peaks in the mixture came from a single compound, namely gracilioether L (Table S9).

² Peak is a number that identifies the order that the peaks were abstracted from the raw data.

peak ¹	position ²	δ _H	δ _c	distance
16	11	6.63	154.9	3.51%
1	5	6.47	142.1	1.00%
21	18	0.77	8.2	0.94%
3	21	3.65	51.1	0.75%
18	16	1.16	12.2	0.47%
2	2	4.85	84.0	0.40%
9	10	2.07	45.9	0.36%
4	9α	1.46	35.2	0.31%
14	8α	1.18	22.4	0.22%
12	14	2.24	26.9	0.18%
10	17β	1.78	32.0	0.17%
20	15	2.20	19.5	0.17%
19	9β	1.31	35.2	0.16%
5	19α	1.50	28.3	0.14%
6	7β	1.73	38.5	0.14%
15	8β	1.15	22.4	0.14%
11	20	0.85	12.0	0.13%
17	12	6.02	132.2	0.09%
13	19β	1.35	28.3	0.09%
8	17α	1.85	32.0	0.08%
7	7α	1.83	38.5	0.04%

Table S9. Atomic novelty scores for gracilioether L

¹ Peak is a number that identifies the order that the peaks were abstracted from the raw data.

² Position identifies the atom number based on those given in Ueoka, R.; Nakao, Y.; Kawatsu, S.; Yaegashi, J.; Matsumoto, Y.; Matsunaga, S.; Furihata, K.; van Soest, R. W. M.; Fuestani, N. *J. Org. Chem.* **2009**, *74*, 4203-4207.

Table S10. NMR spectral data for gracilioether L in CD₃OD



gracilioether L

Position	δ _c , Туре	δ _H , mult (<i>J</i> in Hz)	¹ H- ¹ H COSY	¹ H- ¹³ C HMBC
1	169.3, C	-		
2	84.0,CH	4.85, s	5w	3,4
3	174.2,C	-		
4	141.4,C	-		
5	142.1,CH	6.47, t (1.7)	2w,15	1w,3,4,6,15
6	99.7,C	-		
7α	38.5 CH2	1.83, m	7β,8β	5w,6w,8,9,17
7β	00.0,0112	1.73, m	7α,8α	5w,6w,8,9,17w
8α	22.4 CH ₂	1.18, m	7α,7β,8β,9β	6,7,9,10
8β	22.1,0112	1.15, m	7α,7β,8α,9α	6,7,9,10
9α	35.2 CH ₂	1.46, m	8β,10	7,8,10,11,19w
9β	00.2,0112	1.31, m	8α,10	7,8,10,11,19w
10	45.9,CH	2.07, m	9α,9β,11,19α,19β	8,9,11,12,19,20
11	154.9,CH	6.63, dd (16.0, 9.2)	10,12	9,10,13,19
12	132.2,CH	6.02, d (0.8, 16.0)	11,14w	9w,10,13,14,19w
13	201.3,C	-		
14	26.9,CH ₃	2.24, s	11w	11,12,13
15	19.5,CH ₂	2.20, qt (7.4,1.7)	5,16	3,4,5,16
16	12.2,CH ₃	1.16, t (7.4)	15	4,15
17α	32.0 CH ₂	1.85, m	18	5,6,7,18
17β	02.0,0112	1.78, q (7.2)	18	5,6,7w,18
18	8.2,CH ₃	0.77, t (7.4)	17α,17β	6,17
19α	28.3 CH ₂	1.50, m	10,19β,20	9,10,11,20
19β		1.35, m	10,19α,20	9,10,11,20
20	12.0,CH ₃	0.85, t (7.5)	19α,19β	10,19
21	51.1,CH ₃	3.65, s		1



Figure S1. Peak comparative analyses for cyclomarin A. The structures producing the top prioritized peaks in cyclomarin A are compared with the compounds producing their closest peak within the database as shown in Fig. 2 of the manuscript. The closest peak to B1 was from a side chain methyl of an *N*-methylvaline residue in desmethoxymajusculamide C. Interestingly, both the methyl in desmethoxymajusculamide C and methylene within cyclomarin A were directly proximal to an *N*-methylated amide and shared a comparable environment. The second and third peaks B2 and B3 were close to peaks in pregnenolone sulfate and uvaol, respectively. While the former was not a good fit, the later demonstrated a very similar chemical shift environment with the C53 in cyclomarin A sharing a common motif (blue circle) with uvaol. Peaks B4 and B5 showed also similar correlations with methyl groups (cyclomarin A *versus* cortisone) and α -protons on an amino acid within a cyclic peptide or despipeptide. Remarkably, this small database was able to return structures for each peak with a reliable counterpart.



Figure S2. Peak comparative analyses for gracilioether L. The closest peak in the database to C1 was the β -position of traumatic acid, a functionality that directly correlated with the β -position of the *trans*-enone in gracilioether L. Peak C2 again shared remarkable similarity to its most proximal peak. Here, C2, a δ proton within an unconjugated ester, was proximal to an olefin peak that correlated to δ proton of an unsaturated ketone within canthaxanthin. The closest peak to C3 also contained a high degree of similarity being contained within an ethyl group proximal to hydrogen bond donating oxygen atom and a carbonyl. Peak C4 did not show comparable peaks due to a lack of methyl esters in our database. The latter point suggests the needs to develop an intelligent database, one that offers clear predictions for each peak and enables one to generate structural assignments. Eventually, this would need to be paired with correlation data from 2-bond and 3-bond couplings from spectra such as ¹H-¹³C HMBC spectra to automate *de novo* structural assignment.



Figure S3. Peak shift analyses for cyclomarin A. Our NMR studies were conducted in CD₃OD while the reported characterization of isolated cyclomarin A [M. K. Renner, Y.-C- Shen, X.-C. Cheng, P. R. Jensen, W. Frankmoeller, C. A. Kauffman, W. Fenical, E. Lobkovsky, J. Clardy, *J. Am. Chem. Soc.* **1999**, *121*, 112736] (isolation data) and material produced *via* total synthesis [P. Barbie, U. Kazmaier, *Org. Lett.* **2016**, *18*, 204-7] was conducted in CDCl₃. As noted in these publications the chemical shifts and coupling constants of cyclomarin A modulate according to concentration and amounts of water present. **a)** Comparison of the proton chemical shifts from cyclomarin A isolated herein in CDCl₃ against the isolation data in CDCl₃. **b)** Comparison of the proton chemical shifts from cyclomarin A isolated herein in CD₃OD against the isolation data in CDCl₃. **c)** Comparison of the carbon chemical shifts from cyclomarin A isolated herein in CDCl₃. Both proton in b) and carbon c) shift perturbations illustrate the complexities associated with the use of different solvents.



Figure S4. Structure elucidation of gracilioether L. Gracilioether L was isolated as a wax with molecular formula $C_{21}H_{32}O_4$ inferred by high resolution ESI HRMS (M+Na⁺, *m/z* 371.2193 calcd. 371.2198). The ¹H-¹³C HSQC indicated the presence of 3 ethyl groups, 3 contiguous methylenes, 1 acyl group, a carbomethoxyl, a sp³ methine, an unusually high field sp² methine, a 1,2, disubstituted double bond, and a trisubstituted double bond. ¹H-¹H COSY correlations defined a spin system consisting of the disubstituted double bond (H11,H12), the methine (H10), one of the ethyl groups (H19,H20) and the three adjoining methylenes (H9,H8,H7). ¹H-¹³C HMBC correlations placed the acetyl group (H14 and C13) to the other side of the disubstituted double bond (H12). ¹H-¹³C HMBC correlations to the trisubstituted double bond (H5) identified three guaternary carbons (C3,C4,C6) that were also linked to the remaining two ethyl groups and the highly upfield sp² methine. A literature search for similar chemical shifts suggested the trisubstituted cyclic ether framework. Initially, we envisioned C2 (δ_{C} 84.0) as an oxygenated methine but subsequently found it to be a part of a conspicuous furanylidene motif. The unusual chemical shifts of this group have been remarked upon several times [R. J. Capon, S. Singh, A. Sadaquat, S. Subramaniam, Aust. J. Chem. 2005, 58, 18-20 or D. B. Stierle, D. J. Faulkner, J. Org. Chem., 1980, 45, 3396-3401]. HMBC correlations positioned the remaining ethyl groups on the five membered ring and located the methoxyl as part of a methyl ester attached to the Δ^2 trisubstituted double bond. The C11-C12 double bond was assigned the trans configuration based on the 16.0 Hz coupling between H11 and H12. NOEs from H2 to H15 and H16 defined the Z geometry about the C2-C3 double bond.

Note: The stereochemistry at C6 and C10 could not be determined by NMR methods and would likely require validation by chemical synthesis.

Figure S5. ¹H-¹³C HSQC database







Figure S7. Profiled ¹H-¹³C HSQC spectrum of bromophycolide A



Figure S8. ¹H-¹³C HSQC(600 MHz) spectrum of strychnine in CD₃OD



Figure S9. Profiled ¹H-¹³C HSQC spectrum of strychnine







f1 (ppm)

Figure S11. Profiled ¹H-¹³C HSQC spectrum of brusatol







Figure S13. Profiled ¹H-¹³C HSQC spectrum of paclitaxel







Figure S15. Profiled ¹H-¹³C HSQC spectrum of the CNB-982 extract









Figure S17. Profiled $^{1}H^{-13}C$ HSQC spectrum of cyclomarin A



Figure S18. ¹H NMR (600 MHz) spectra of cyclomarin A in CD₃OD



















Figure S22. ¹H NMR (600 MHz) spectra of cyclomarin A in CDCl₃









Figure S24. Profiled ¹H-¹³C HSQC spectrum of the IM06-19 extract







Figure S26. Profiled ¹H-¹³C HSQC spectrum of of gracilioether L



Figure S27. ¹H NMR (600 MHz) spectra of gracilioether L in CD₃OD













